New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENI...(ore aggressive BP target of 130/80 mm H...),Health

Date:5/14/2008

ore aggressive BP target of < 130/80 mm Hg (placebo: 6.9%). In addition, in another sub analysis, the study demonstrated that nearly seven out of ten (cumulative 69%) with stage 2 hypertension were able to reach the < 140/90 mm Hg blood pressure goal recommended by the JNC 7 (placebo: 16.9%). Stage 1 hypertension is defined by the JNC 7 as systolic blood pressure (SBP) of 140-159 mm Hg or diastolic blood pressure (DBP) of 90-99 mm Hg; Stage 2 hypertension is defined as 160/100 mm Hg or higher(1).

"These results are very encouraging as we in the cardiovascular community have been advocating to more aggressively fight hypertension," said Suzanne Oparil M.D., Director, Vascular Biology & Hypertension Program, University of Alabama at Birmingham, lead investigator of the study and President of ASH. "The study showed the ability of a regimen of BENICAR and BENICAR HCT to lower blood pressure beyond 140/90 mm Hg to the more aggressive normotensive target."

In the overall study, both stage 1 and stage 2 patients receiving BENICAR HCT 40/25 mg saw their seated systolic blood pressure (SeSBP) drop a mean of 23 mm Hg from a mean SBP baseline of 158 mm Hg (placebo: -2.6 mm Hg). In addition, more than one in four patients (27 percent) reached normotension, defined as < 120/80 mm Hg (placebo: 1.5%).

Of this study patient population, those with stage 2 hypertension achieved very good results with this regimen of BENICAR and BENICAR HCT. Of those titrated up to the maximum dose of 40/25mg, a cumulative 69 percent achieved a BP of < 140/90 mm Hg (placebo: 17%) while a cumulative 15 percent achieved a BP of < 120/80 mm Hg (placebo: 1.5%). For those with stage 2 hypertension, the average BP reduction for those patients on BENICAR 40/25 mg was 25/14 mm Hg (placebo: 6.2/1.9 mm Hg).

Hypertension, also known as high blood pressure, affects approximately 73 million people in the United States and approximately one billion worldwide(2,3). Called the "silent kill
'/>"/>

SOURCE Daiichi Sankyo, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
10. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
11. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer